Camrelizumab plus chemotherapy with or without thalidomide for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination treatment for people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. It combines an immunotherapy drug (camrelizumab) with chemotherapy, and may also add a drug called thalidomide to see if it improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced (stage IIIB or IV) non-small cell lung cancer confirmed by biopsy or cytology.
- You cannot have had any previous treatment for advanced lung cancer. If you had prior chemotherapy or radiation for earlier-stage disease, at least 12 months must have passed since the last dose.
- You must have at least one tumor that can be measured by CT or MRI.
- You must be in generally good health, able to care for yourself, and have a life expectancy of at least 3 months.
- You must not have certain gene changes (EGFR or ALK) that have approved targeted therapies, and you must not have active brain metastases or serious autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests adding camrelizumab (an immune therapy) to standard chemotherapy before surgery for people with triple-negative breast cancer that has not spread. It aims to improve how much the tumor shrinks before and around the time of surgery.
This trial tests adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery for people with stage IIIA-IIIB non-small cell lung cancer. The goal is to see if this combination shrinks tumors more effectively before removal.
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
This trial tests a new combination of an immunotherapy drug (camrelizumab) with chemotherapy (nab-paclitaxel) and an allergy medicine (levocetirizine) for people with triple negative breast cancer that has spread or come back. The goal is to see if this combination can shrink tumors and improve outcomes.
This study tests whether adding camrelizumab (an immune treatment) to standard chemoradiotherapy can control advanced esophageal squamous cell cancer. It is meant for people who have not had any prior whole-course cancer medicines for this cancer stage.
This Phase 2 study looks at whether adding an immunotherapy medicine (camrelizumab) to standard chemotherapy after lung surgery can help prevent lung cancer from coming back. It is for people with stage IIA–IIIA non-small cell lung cancer who cannot use targeted (mutation-based) adjuvant therapy.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.